Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges
By Paul Ziobro
Gilead Sciences posted higher first-quarter sales, but swung to a steep loss due to charges related to recent acquisitions, prompting the company to cut its per-share profit outlook.
The Foster City, Calif.-based biopharmaceutical company reported a loss of $4.17 billion, or $3.34 a share, compared with a profit of $1.01 billion, or 81 cents a share, in the same quarter a year ago.
The latest quarter's results were impacted by a $3.9 billion in-process research and development charge related to its recent $4.3 billion acquisition of CymaBay Therapeutics, as well as a pretax impairment of $2.4 billion related to assets acquired from Immunomedics in 2020.
Adjusted for certain items, Gilead said its per-share loss came to $1.32 a share. Analysts were looking a loss of $1.49 a share, according to FactSet.
Total revenue rose about 5% to $6.67 billion, ahead of analyst expectations for $6.36 billion, primarily due to higher sales of HIV, oncology and liver disease products.
For the full-year, Gilead now expects per-share earnings of between 10 cents and 50 cents, down from its prior view of $5.15 to $5.55. On an adjusted basis, the company expects per-share earnings of $3.45 to $3.85, down from a prior range of $6.85 to $7.25.
It backed its top-line outlook.
Write to Paul Ziobro at paul.ziobro@wsj.com
-0-
Gileadisprovidingfull-year2024guidancebelow:
• Totalproductsalesbetween$27.1billionand$27.5billion.
• Totalproductsales,excludingVeklury,between$25.8billionand$26.2billion.
• TotalVeklurysalesofapproximately$1.3billion.
• DilutedEPSbetween$5.15and$5.55.
• Non-GAAPdilutedEPSbetween$6.85and$7.25.
(END) Dow Jones Newswires
April 25, 2024 16:39 ET (20:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom